High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform

EpiScan permits the targeted evaluation of potential MHC-I ligands amongst pre-defined libraries of >100,000 peptides.

Schematic representation of the EpiScan approach and logoplots. EpiScan relies on the well-established principle that MHC-I molecules are only trafficked to, and maintained on, the cell surface after stably binding a suitable peptide in the ER. (a) Knocking out ERAP1/2 and the TAP1/2 depletes the ER of short peptides, thus empty MHC-I molecules remain in the ER. (b) Under these conditions, delivery of exogenous peptide into ER, via the lentiviral EpiScan vector, that binds MHC-I restores cell surface MHC-I. (c) EpiScan-derived logoplots of two of the most common MHC-I alleles, A*02:01 and A*03:01.

See EpiScan here.

Peter’s Other First Author Publications

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. PNAS. 2020
Read here

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017
Read here

Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. J. Am. Chem. Soc. 2016
Read here

Versatile in vivo regulation of tumor phenotypes by dCas9 mediated transcriptional perturbation. PNAS. 2016
Read here

All Other Publications